News
SVRA
5.06
+1.20%
0.06
Weekly Report: what happened at SVRA last week (0921-0925)?
Weekly Report · 7h ago
Notable Thursday Option Activity: SVRA, CAR, SPCX
NASDAQ · 3d ago
Weekly Report: what happened at SVRA last week (0914-0918)?
Weekly Report · 09/21 09:19
Weekly Report: what happened at SVRA last week (0907-0911)?
Weekly Report · 09/14 09:20
Weekly Report: what happened at SVRA last week (0831-0904)?
Weekly Report · 09/07 09:19
Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative
Simply Wall St · 09/01 16:27
Weekly Report: what happened at SVRA last week (0824-0828)?
Weekly Report · 08/31 09:20
Piper Sandler Sticks to Their Buy Rating for Savara (SVRA)
TipRanks · 08/26 11:35
Does Phase 3 IMPALA-2 aPAP Data at ERS 2026 Change The Bull Case For Savara (SVRA)?
Simply Wall St · 08/25 15:25
Savara announces presentations of Results from Phase 3 trial of Molgramostim
TipRanks · 08/24 20:10
Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS Congress
Benzinga · 08/24 20:08
Weekly Report: what happened at SVRA last week (0817-0821)?
Weekly Report · 08/24 09:20
Why Savara (SVRA) Is Getting Attention Today
Simply Wall St · 08/24 06:16
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), AptarGroup (ATR) and Abbott Laboratories (ABT)
TipRanks · 08/21 10:50
Savara Announces New Employment Inducement Grant
Barchart · 08/20 15:05
Weekly Report: what happened at SVRA last week (0810-0814)?
Weekly Report · 08/17 09:21
Savara (SVRA) Faces A Fresh Valuation Test As Losses Widen And Shelf Filing Looms
Simply Wall St · 08/16 14:18
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf
Simply Wall St · 08/13 02:22
LifeSci Capital Remains a Buy on Savara (SVRA)
TipRanks · 08/12 11:55
Guggenheim Remains a Buy on Savara (SVRA)
TipRanks · 08/12 11:16
More
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara Inc through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.